Advertisement
CRVO vs VRCA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVO is a Hold and VRCA is a Hold.
CRVO's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for CRVO moved out of overbought territory on October 09, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In 18 of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRVO as a result. In 94 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CRVO turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 48 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CRVO moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CRVO broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRVO entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for CRVO crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +10.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVO advanced for three days, in 183 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.758) is normal, around the industry mean (26.782). P/E Ratio (4.727) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CRVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for VRCA turns negative, indicating new downward trend
VRCA saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 81 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for VRCA turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VRCA entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for VRCA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRCA advanced for three days, in 229 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
VRCA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.349) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (2.496) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. VRCA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRCA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRVO | VRCA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 56 Fair valued | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 84 | 82 | |
P/E GROWTH RATING 1..100 | 49 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRVO's Valuation (56) in the Biotechnology industry is in the same range as VRCA (62) in the Pharmaceuticals Major industry. This means that CRVO’s stock grew similarly to VRCA’s over the last 12 months.
CRVO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that CRVO’s stock grew similarly to VRCA’s over the last 12 months.
CRVO's SMR Rating (99) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that CRVO’s stock grew similarly to VRCA’s over the last 12 months.
VRCA's Price Growth Rating (82) in the Pharmaceuticals Major industry is in the same range as CRVO (84) in the Biotechnology industry. This means that VRCA’s stock grew similarly to CRVO’s over the last 12 months.
CRVO's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for VRCA (100) in the Pharmaceuticals Major industry. This means that CRVO’s stock grew somewhat faster than VRCA’s over the last 12 months.
| CRVO | VRCA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| Advances ODDS (%) | 12 days ago 81% | 20 days ago 87% |
| Declines ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRVO’s FA Score shows that 0 FA rating(s) are green while VRCA’s FA Score has 0 green FA rating(s).
- CRVO’s FA Score: 0 green, 5 red.
- VRCA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRVO’s TA Score shows that 3 TA indicator(s) are bullish while VRCA’s TA Score has 4 bullish TA indicator(s).
- CRVO’s TA Score: 3 bullish, 7 bearish.
- VRCA’s TA Score: 4 bullish, 4 bearish.
Price Growth
CRVO (@Biotechnology) experienced а -30.43% price change this week, while VRCA (@Biotechnology) price change was -12.53% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
CRVO is expected to report earnings on Nov 16, 2026.
VRCA is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CRVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRVO has been loosely correlated with SLBT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVO jumps, then SLBT could also see price increases.
| Ticker / NAME | Correlation To CRVO | 1D Price Change % | ||
|---|---|---|---|---|
| CRVO | 100% | -0.44% | ||
| SLBT - CRVO | 39% Loosely correlated | -1.29% | ||
| NMRA - CRVO | 35% Loosely correlated | +10.96% | ||
| CADL - CRVO | 30% Poorly correlated | -8.08% | ||
| RCUS - CRVO | 30% Poorly correlated | -3.07% | ||
| VRCA - CRVO | 29% Poorly correlated | -4.89% | ||
More | ||||
VRCA and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with SVRA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then SVRA could also see price increases.
| Ticker / NAME | Correlation To VRCA | 1D Price Change % | ||
|---|---|---|---|---|
| VRCA | 100% | -4.89% | ||
| SVRA - VRCA | 37% Loosely correlated | -6.12% | ||
| RYTM - VRCA | 36% Loosely correlated | -2.05% | ||
| KTTA - VRCA | 35% Loosely correlated | +2.41% | ||
| PHVS - VRCA | 33% Poorly correlated | -6.41% | ||
| SANA - VRCA | 33% Poorly correlated | -8.28% | ||
More | ||||